Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15562694 | 1.00 | ALDH1A1 (0.34) | ALDH1A1USP2RECQLNPC1RAB9A | |
| SCHEMBL2493593 | 1.00 | ALDH1A1 (0.34) | ALDH1A1USP2RECQLNPC1RAB9A | |
| SCHEMBL6219536 | 0.83 | ALDH1A1 (0.35) | ALDH1A1USP2RECQLGAAMAPT | |
| SCHEMBL6213276 | 0.79 | NOS1 (0.38) | ALDH1A1USP2RECQLGAAMAPT | |
| SCHEMBL6213273 | 0.79 | NOS1 (0.38) | ALDH1A1USP2RECQLGAAMAPT | |
| SCHEMBL16792283 | 0.78 | — | — | |
| SCHEMBL18339066 | 0.78 | — | — | |
| SCHEMBL6621084 | 0.77 | LMNA (0.33) | ALDH1A1USP2RECQL | |
| SCHEMBL6279198 | 0.77 | USP2 (0.32) | ALDH1A1USP2RECQL | |
| SCHEMBL6279200 | 0.77 | USP2 (0.32) | ALDH1A1USP2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709722-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233547-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-3080128-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3298017-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2019-08-14 | — | — | EP | disclosed |
| US-10208067-B2 | Compounds for treating spinal muscular atrophy | HOFFMANN-LA ROCHE INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180194781-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. (US) | 2018-07-12 | — | — | US | disclosed |
| EP-3298017-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | H. Hoffnabb-La Roche Ag (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-9873703-B2 | Imidazopyridazine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-01-23 | — | — | US | disclosed |
| US-20160376275-A1 | Imidazopyridazine Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-12-29 | — | — | US | disclosed |
| WO-2016184832-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-24 | — | — | WO | disclosed |
| WO-2014020531-A1 | IMIDAZO[1,2-B]PYRIDAZIN-6-AMINE DERIVATIVES AS KINASE JAK-2 INHIBITORS | CELON PHARMA S.A. (PL) | 2014-02-06 | — | — | WO | disclosed |
| EP-2379557-B1 | AMINO PYRAZOLE COMPOUND | LILLY CO ELI (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2379557-A1 | AMINO PYRAZOLE COMPOUND | Eli Lilly and Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-7897600-B2 | Amino pyrazole compound | ELI LILLY AND COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100286139-A1 | AMINO PYRAZOLE COMPOUND | ELI LILLY AND COMPANY (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010074947-A1 | AMINO PYRAZOLE COMPOUND | ELI LILLY AND COMPANY (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100152181-A1 | AMINO PYRAZOLE COMPOUND | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| EP-1362050-B1 | PYRIMIDINE DERIVATIVES FOR INHIBITION OF CELL-PROLIFERATION | ASTRAZENECA AB (SE) | 2005-02-02 | — | — | EP | disclosed |
| US-6844341-B2 | Pyrimidine derivatives for inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2005-01-18 | — | — | US | disclosed |
| US-20040097506-A1 | Pyrimidine derivatives for inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376275-A1 | Imidazopyridazine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | ALDH1A1 217/4885USP2 3509/4885RECQL 1878/4885 |
| US-20040097506-A1 | Pyrimidine derivatives for inhibition of cell proliferation | TYMP, TK1, TYMS | ALDH1A1 127/4885USP2 4225/4885RECQL 23/4885 |
| US-20100286139-A1 | AMINO PYRAZOLE COMPOUND | MCL1, MYC, PML | ALDH1A1 2620/4885USP2 3065/4885RECQL 4807/4885 |
| US-20180194781-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, PYGM, CPT1B | ALDH1A1 770/4885USP2 2940/4885RECQL 135/4885 |
| US-20100152181-A1 | AMINO PYRAZOLE COMPOUND | MCL1, MYC, PML | ALDH1A1 2620/4885USP2 3065/4885RECQL 4807/4885 |
| US-10208067-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, PYGM, CPT1B | ALDH1A1 770/4885USP2 2940/4885RECQL 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.